CSIR-IICT signs MoU with 101 Therapeutics, Israel for COVID-19 drug
CSIR-IICT will be the knowledge partner for the clinical trial study and 101 Therapeutics, a CRO will manufacture the drug
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CSIR-IICT
CSIR-IICT, Anthem Biosciences partner to produce anti-COVID drug 2-DG
Anthem Biosciences is in the process of filing an application for getting the approval from DCGI and will subsequently manufacture…
Bharat Biotech, Biovet, Sapigen Biologix enter into research pact with CSIR-IICT
To collaborate on the development of novel platform technologies for biotherapeutics and vaccines to support indigenous,…
CSIR and Mylan in partnership to develop therapeutic options for COVID–19 management
The application for the clinical trials has been submitted to DCGI for regulatory approval
APIIC signs MoU with CSIR-IICT to establish a bulk drug park
CSIR-IICT will be the knowledge partner and offer technical support for the proposal to be submitted to the DoP
CSIR-IICT develops cost effective process technology for Favipiravir
The research lab announced that its had transferred the technology to Cipla, which has recently DCGI for permission to launch the…
IICT develops synthetic process for Favipiravir, transfers to Cipla
As a collaborative effort with industry, Hyderabad-based CSIR-IICT transferred the entire process and significant quantities of…
CSIR identifies top 25 drugs/drug candidates for repurposing
Favipiravir, a broad-spectrum inhibitor of viral RNA polymerase, emerges as one of the most promising drugs
Sun Pharma Announces Licensing Agreement With CSIR-IICT
This collaboration with CSIR-IICT for developing new drugs is part of our broader strategy for enhancing our global specialty…